After completing this activity, the participant should be better able to: Explain MAFLD/MASH pathogenesis and the role that cardiovascular and cardiometabolic risk factors, including obesity and diabetes, play in MASH progression in order to improve the identification of MASH Recognize current and emerging approaches and tools to screen and diagnose MAFLD and MASH in clinical practice Summarize the current guidelines and recommendations for treatment of MASH, including recent consensus statements Review the rationale, efficacy and safety of GLP-1 RAs for the treatment of MASH List other emerging agents that are in clinical development for MASH
- Provider:Partners for Advancing Clinical Education (PACE)
- Activity Link: https://cme.tarsusmedicaleducation.com/cardiometabolic-health-congress-cmhc-/content/emerging-role-glucagon-peptide-1-receptor-agonists-MASH_1604
- Start Date: 2024-05-06 05:00:00
- End Date: 2024-05-06 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - Commercial Support: Source: Novo Nordisk (Any division) - Amount: 180650.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest